Vol. 20/No. 14 | OncologyLive

New Agents Emerge for Elusive NSCLC Targets

July 22, 2019

Although immunotherapy has become an important modality for treating non–small cell lung cancer, the development of new strategies for targeting oncogenic drivers of disease in subgroups of patients is moving forward at a brisk pace.

Statistics Show Increase in US Cancer Survivors

July 20, 2019

The growth and aging of the population combined with advances in the early detection and treatment of cancer have resulted in a growing population of survivors across the nation, according to a study from the American Cancer Society and the National Cancer Institute.

Investigators Seek to Boost Surgical Cures in RCC With Immune Priming

July 18, 2019

In the phase III PROSPER trial, investigators will attempt a novel approach in localized renal cell carcinoma: priming the immune system prior to nephrectomy with neoadjuvant nivolumab and continuing with adjuvant blockade. The study will be the first to combine neoadjuvant and adjuvant immunotherapy with standard of care nephrectomy.

NTRK Gene Fusions: Finding the "Golden Ticket" in Oncology

July 18, 2019

During an OncologyLive Peer Exchange, the panelists discuss some of the challenges they face when conducting molecular testing, including determining which patients to test, when to test, and how to test to ensure that no golden tickets, such as NTRK gene fusions, are missed. They also discuss the data surrounding TRK inhibitors and their experiences using these agents.

CMS Unveils Proposed Radiation Oncology Model of Care

July 18, 2019

Until now, radiation oncology (RO) has remained largely untouched by the valuebased initiatives of the Centers for Medicare and Medicaid Services. The federal agency aims to change that with a proposed RO Model of care that would promote site-neutral payment and take away incentives for volume-based billing.

Fresh Approaches to RT Improve Outcomes in Retroperitoneal Sarcoma

July 15, 2019

Each year, 10% to 15% of patients with soft-tissue carcinomas receive a diagnosis of rare retroperitoneal sarcoma (RPS), an aggressive disease that typically recurs in 26% of cases and has a 47% to 67% five-year overall survival rate. New radiation therapies hold potential to decrease treatment time and provide local control of RPS.